Superior Planning, LLC’s Taysha Gene Therapies TSHA Stock Holding History

Superior Planning, LLC’s Portfolio TSHA Stock Details TSHA Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q3	$3.17K	Buy	+650	New	+$3.75K	﹤0.01%	1388

Other funds holding TSHA

Fidelity Investments Boston, Massachusetts $2.32T AUM 44.66% 1-Year Est. Return

State Street Boston, Massachusetts $3.44T AUM 36.12% 1-Year Est. Return

Siren LLC Greenwich, Connecticut $4.23B AUM 121.47% 1-Year Est. Return

Geode Capital Management Boston, Massachusetts $1.92T AUM 36.1% 1-Year Est. Return

Aberdeen Group Edinburgh, United Kingdom $72.4B AUM 31.32% 1-Year Est. Return

Pictet Asset Management Carouge, Switzerland $106B AUM 32.76% 1-Year Est. Return

Capitolis Liquid Global Markets New York $22.4B AUM 40.52% 1-Year Est. Return

First Trust Advisors Wheaton, Illinois $170B AUM 38.25% 1-Year Est. Return

Quantum Private Wealth Tampa, Florida $391M AUM 50.76% 1-Year Est. Return

JP Morgan Chase New York $1.84T AUM 33.86% 1-Year Est. Return

Superior Planning, LLC's TSHA Position: Q3 2026 in Review

Superior Planning, LLC opened a new position in Taysha Gene Therapies (TSHA) in Q3 2026: 650 shares worth $3.17K. The stake represents ﹤0.01% of the portfolio and ranks #1388 among its holdings.

106 funds tracked by Wall St. Rank hold TSHA as of Q3 2026.

Superior Planning, LLC held 650 shares of Taysha Gene Therapies worth $3.17K as of Q3 2026.
Taysha Gene Therapies was a new Superior Planning, LLC position in Q3 2026.
Taysha Gene Therapies made up ﹤0.01% of Superior Planning, LLC's portfolio in Q3 2026, its #1388 holding.
106 funds tracked by Wall St. Rank held Taysha Gene Therapies as of Q3 2026.

Based on Superior Planning, LLC's 13F filing for Q3 2026, filed 12 Nov 2026.